Nektar inhaled anti infective given orphan designation
Orphan products are developed to treat diseases or conditions that affect fewer than 200,000 people in the US. The orphan drug act provides a seven-year period of exclusive
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.